UNASSIGNED: @entity201 is often unresectable at the time of the initial diagnosis, and the provision of a definite palliative benefit is important in @entity1 with unresectable @entity201 . The aim of the present study was to evaluate the safety of percutaneous biliary stenting and to analyze whether percutaneous biliary stenting combined with radiotherapy (RT) prolonged the stent patency and survival time of @entity1 . In total, the cases of 38 @entity1 with unresectable @entity201 that underwent percutaneous biliary stenting at the Navy General Hospital were retrospectively reviewed in the present study. @entity1702 ( @entity1702 ) combined with RT was administered to 25 @entity1 , and @entity1702 alone was administered to 13 @entity1 . The records of early complications subsequent to percutaneous biliary stenting were collected, and the stent patency and survival times of @entity1 were analyzed and compared between the two groups. The technical success rate of the procedure was 100% and the successful drainage rate was 86.8%. The overall early complication rate was 15.8% and the procedure-associated mortality rate was 2.6%. The median stent patency was 326 days in the @entity1702 +RT group and 196 days in the @entity1702 group (P=0.022). The @entity1702 +RT group (median, 367 days) demonstrated a longer survival time compared with the @entity1702 group (median, 267 days; P=0.025). Percutaneous biliary stenting offers a safe and effective method for the palliative treatment of @entity1 with unresectable @entity201 , and percutaneous biliary stenting combined with RT may prolong stent patency and @entity1 survival time.

Percutaneous biliary stenting combined with radiotherapy as a treatment for unresectable XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity201 :: ('MESH:D018281', 'Disease') :: ['hilar cholangiocarcinoma', 'Hilar cholangiocarcinoma'] @entity1702 :: ('MESH:D013651', 'Disease') :: ['Uncovered metallic stenting', 'UMS']
@entity201 :: (MESH:D018281,Disease) :: ['hilar cholangiocarcinoma']
